Navigation Links
Proceedings of the National Academy of Sciences Report Superiority of Human Growth Hormone Generated with Ambrx Technology
Date:5/25/2011

SAN DIEGO, May 25, 2011 /PRNewswire/ -- Ambrx Inc. today announced that data from a Phase 1/2 study, published online ahead of print on May 16 by Proceedings of the National Academy of Sciences, demonstrate the safety, efficacy and superior dosing frequency of ARX201, a sustained action human growth hormone, compared to therapy with native hormone.

The study evaluated adult GH-deficient (AGHD) patients treated with ARX201, which was generated with Ambrx's ReCODE™ technology. ARX201 was shown to have a half-life in patients of four days and to potentially be suitable for weekly dosing, which is superior to current therapy that requires daily dosing. Insulin-like growth factor 1 (IGF-1) a clinically validated biomarker of growth hormone activity was restored to normal ranges with weekly dosing.  ARX201 was found to be safe and well tolerated with repeat dosing.

"This report provides clinical validation of Ambrx technology, which constitutes site-directed protein medicinal chemistry," said Ho Cho, Ph.D., Chief Technology Officer of Ambrx. "ARX201 represents a best in class growth hormone optimized for efficacy, safety and patient convenience. Additionally, Ambrx has successfully scaled the manufacturing process to support advanced product development and eventual commercialization."

The study enrolled 22 AGHD patients who had not received growth hormone replacement therapy in the past six months.  Patients received weekly injections of ARX201 for up to 26 weeks.  ARX201 dose was determined through measurement of IGF-1, the standard indicator for growth hormone therapy.  Efficacy in patients included decreased truncal fat mass and total body fat, while lean body mass levels increased.

About ARX201

ARX201 is a long-acting rDNA-derived human GH drug candidate being developed by Ambrx for the treatment of growth hormone deficiencies. A Phase 2b clinical trial of ARX201 in adult patients with growth hormone deficiency was successfully completed in 2010. This and previous studies have demonstrated that ARX201 has improved pharmacological performance relative to existing growth hormone drugs, including the potential for much less frequent dosing.  ARX201 was generated through a process using Ambrx's ReCODE™ technology, which enables optimal protein medicinal chemistry. Through this approach, Ambrx discovered site specific mono-PEG hGH molecules optimized for potency and duration of action.  

About Ambrx

Ambrx Inc. is a clinical stage biopharmaceutical company using its transformational technology in discovery of best-in-class therapeutics, including antibody drug conjugates and novel proteins of unprecedented potential. The company is developing ARX201, a sustained action growth hormone that has successfully completed Phase 2b clinical trials. Ambrx has validated its biologics platform through partnerships with Eli Lilly, Merck-Serono, Pfizer, Roche and Merck & Co Inc.  Ambrx is advancing a robust portfolio of product candidates optimized for efficacy, safety and ease of use in multiple therapeutic areas.  For additional information, visit www.ambrx.com.

Media Contact:

David Schull or Ian Stone
Russo Partners
T: (212) 845-4271
T: (619) 528-2220
david.schull@russopartnersllc.com
ian.stone@russopartnersllc.com


'/>"/>
SOURCE Ambrx Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros Announces Publication of MASP-2 Data in Proceedings of the National Academy of Sciences
2. Data Published in Proceedings of National Academy of Sciences Highlights Potential of Micromets BiTE Antibody Platform
3. London Genetics Conference Proceedings Published in Drug Discovery Today
4. Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement
5. Mayo Clinic Proceedings: A Comprehensive Review of Addiction to Prescription Painkillers Among Patients and Physicians
6. Mayo Clinic Proceedings Reviews Deep Brain Stimulation to Treat Psychiatric Diseases
7. US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
8. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
9. Mayo Clinic Proceedings Contributors Highlight Research Findings About Cardiovascular Benefits Associated With Omega-3 Fatty Acids
10. Mayo Clinic Proceedings Contributors Discuss Impact of Donor Organ Allocation System
11. Mayo Clinic Proceedings January Tip Sheet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2017)... Ind. , June 30, 2017 Zimmer Biomet ... quarter sales and earnings conference call will be broadcast live ... a.m. Eastern Time.  A news release detailing the quarterly results ... morning of the conference call. The live audio ... at http://investor.zimmerbiomet.com . It will be archived for replay ...
(Date:6/30/2017)... , June 29, 2017  Axium Pharmaceuticals Inc. is a pharmaceutical ... novel formulations and alternative dosage forms of existing biologically active ... ... on our waterless self-nano emulsifying formula, which is designed to ... We believe the spray will provide fast onset of action ...
(Date:6/20/2017)... and LAGUNA HILLS, Calif. , ... of new data that validate the use of MMprofiler ... patients with multiple myeloma (MM). In a poster presentation ... Hematology Association (EHA) in Madrid, Spain ... MMprofiler for identifying high-risk elderly patients. ...
Breaking Medicine Technology:
(Date:7/20/2017)... ... July 20, 2017 , ... For individuals with extended hospital stays ... beds used in such facilities are specially designed to accommodate patients with a wide ... , An inventor from Rochester, Ind., has invented the patent-pending PORTABLE ARM REST, a ...
(Date:7/20/2017)... ... July 20, 2017 , ... Girl ... bipartisan House and Senate legislation in support of providing girls access to education ... introduced H.R. 2408, the “Protecting Girls’ Access to Education in Vulnerable Settings Act.” ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... Business Architecture Body of Knowledge (BIZBOK® Guide )v 6.0 is now available for ... this effort through Guild collaborative teams. , Non-members may download the Part ...
(Date:7/20/2017)... ... ... Dr. Jig Patel is pleased to announce openings for new patients who ... the difficulties that face people who are missing teeth , he offers education ... dentures and bridges. Not only does an implant improve oral health, it also restores ...
(Date:7/20/2017)... ... July 19, 2017 , ... A July 5th article on ... patients who had received a body contouring procedure reported experiencing a better quality of ... Physicians (BHP), which provides both types of procedures, notes that this report jibes with ...
Breaking Medicine News(10 mins):